Related Experiment Videos
Human flavin-containing monooxygenases
1Human BioMolecular Research Institute, San Diego, CA 92121, USA. JCashman@HBRI.org
Annual Review of Pharmacology and Toxicology
|January 13, 2006
Summary
Human flavin-containing monooxygenase (FMO) metabolizes drugs, sometimes causing toxicity. Genetic variations influence FMO activity, but it offers advantages in drug design due to low induction and inhibition.
Area of Science:
- Biochemistry
- Pharmacology
- Toxicology
Background:
- Human flavin-containing monooxygenase (FMO) enzymes play a crucial role in xenobiotic metabolism.
- FMOs oxygenate diverse nucleophilic chemicals and drugs, typically producing excretable metabolites.
- FMO activity can sometimes lead to the bioactivation of compounds, resulting in toxicity.
Purpose of the Study:
- To review recent findings on the pharmacological and toxicological importance of human FMOs.
- To explore the impact of genetic variability on FMO-mediated metabolism.
- To discuss the implications of FMO properties for drug design and discovery.
Main Methods:
- Literature review of recent scientific information on human FMOs.
- Analysis of FMO's role in drug metabolism and toxicity.
- Comparison of FMO characteristics with cytochrome P450 (CYP) enzymes.
Main Results:
- FMOs generally detoxify chemicals but can also cause bioactivation and toxicity.
- Genetic and splicing variants significantly contribute to interindividual and interethnic differences in FMO activity.
- FMOs exhibit low inducibility and inhibition compared to CYPs, minimizing drug-drug interactions.
Conclusions:
- FMO's unique metabolic profile offers potential advantages in drug design, promoting the development of more drug-like compounds.
- Understanding FMO's role in xenobiotic metabolism is critical for predicting drug efficacy and toxicity.
- Physiological factors influencing FMO function may have clinical implications for human diseases.